Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Cytarabine · Depocyt, NSC-287459

Small molecule · Inhibitor of DNA polymerase · developed by Teva Parenteral

Approved FDA, Jun 1969

3 Registered trials

What is Cytarabine?

Cytarabine is a cytidine antimetabolite with an arabinose sugar moiety that competes with cytidine for incorporation into DNA. It inhibits DNA polymerase and blocks DNA replication and repair, particularly during S phase. It is studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Depocyt, NSC-287459, U-19920, Ara-C, HiDAC
Drug type: Small molecule
Targets: DNA polymerase
Mechanism: Inhibitor of DNA polymerase
Pathways: DNA replication, DNA repair
Therapy area: Oncology
Developer: Teva Parenteral
In trials of: BLRX, SNDX
FDA status: Approved as Depocyt (June 17, 1969), NDA016793
UNII: 04079A1RDZ

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02502968	Phase 2	Acute Myeloid Leukemia	Unknown	BLRX
NCT01838395	Phase 2	Acute Myeloid Leukemia	Completed	BLRX
NCT06226571	Phase 1	Acute Myeloid Leukemias	Active not recruiting	SNDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemias

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z